NCT04336943View on ClinicalTrials.gov

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

June 20, 2024

Study Completion Date

June 6, 2025

Conditions
Biochemically Recurrent Prostate CarcinomaProstate Adenocarcinoma
Interventions
BIOLOGICAL

Durvalumab

Given IV

DRUG

Olaparib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Washington

OTHER